Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 20/20 | 0.67 |
| ▸ | MMP2 | P08253 | 1/20 | 0.59 |
| ▸ | MMP3 | P08254 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 1/20 | 0.59 |
| ▸ | MMP13 | P45452 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6603567 | 0.94 | BMP1 (0.70) | BMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL6599667 | 0.91 | BMP1 (0.66) | BMP1 | |
| SCHEMBL6596928 | 0.91 | BMP1 (0.53) | BMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL6597122 | 0.85 | BMP1 (0.55) | BMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL6600479 | 0.82 | BMP1 (0.72) | BMP1 | |
| SCHEMBL6598828 | 0.82 | BMP1 (0.53) | BMP1 | |
| SCHEMBL6599842 | 0.81 | BMP1 (0.74) | BMP1MMP3 | |
| SCHEMBL6598591 | 0.81 | BMP1 (1.00) | BMP1 | |
| SCHEMBL6600276 | 0.79 | BMP1 (0.68) | BMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL6599670 | 0.79 | BMP1 (0.69) | BMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373264-B1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-22 | — | — | EP | disclosed |
| US-6821972-B2 | ANTISCARRING AGENTS; WOUND HEALING AGENTS; ENZYME INHIBITORS | PFIZER INC. | 2004-11-23 | — | — | US | disclosed |
| US-20030069291-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | PFIZER INC. | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069291-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | PAH, CYP2F1, CYP7A1 | BMP1 449/4885MMP2 3264/4885MMP3 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.